AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

MarketsPricingSign inSign up free

FINGOLIMOD

12 registrations across 4 African markets— 7 active

Markets with FINGOLIMOD

🇹🇳Tunisia
5 registrations
0 active
🇿🇦South Africa
5 registrations
5 active
🇹🇿Tanzania
1 registration
1 active
🇿🇼Zimbabwe
1 registration
1 active

Recent registrations

Brand / ProductMarketHolderStatusExpires
GLOMATIN
CAPSULE
🇿🇼ZimbabweHETERO LABS LTDactiveSept 2030
MELIOR
Gélule / 0.5 mg
🇹🇳TunisiaSAIPHexpiredJul 2023
LUNARIS
Gélule / 0.5 mg
🇹🇳TunisiaLES LABORATOIRES MEDISexpiredAug 2022
LUNARIS
Gélule / 0.5 mg
🇹🇳TunisiaLES LABORATOIRES MEDISexpiredMay 2022
FINGOLINE
Gélule / 0.5 mg
🇹🇳TunisiaTAHA PHARMAexpiredNov 2016
GILENYA
Gélule / 0.5 mg
🇹🇳TunisiaNOVARTIS PHARMA SCHWEIZ AGexpiredMar 2013
FINGOLIMOD ALKEM🇿🇦South AfricaASCEND LABORATORIES (PTY) LTDactiveJan 1900
DOMILO🇿🇦South AfricaAdcock Ingram LimitedactiveJan 1900
FINKEM🇿🇦South AfricaASCEND LABORATORIES (PTY) LTDactiveJan 1900
MYELENEA🇿🇦South AfricaForrester Pharma (Pty) LtdactiveJan 1900
TUVIGIN 0,5 mg🇿🇦South AfricaNovartis South Africa (Pty) LtdactiveJan 1900
GLOMATIN
Capsules
🇹🇿TanzaniaHetero Labs Limitedactive—

FINGOLIMOD in Africa — Regulatory Overview

FINGOLIMOD is registered across 4 African markets with 12 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tunisia, South Africa, Tanzania, Zimbabwe. AfricaRegulatory refreshes this data daily from official government sources.

Of the 12 registrations, 7 (58%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.